#Shanghai #USA #Heart Failure #Pulnovo Medical #PADN Technology

Major Funding Success for Pulnovo Medical

In an exciting development for the medical community, Pulnovo Medical, a leading innovator in medical devices addressing pulmonary hypertension (PH) and heart failure (HF), has successfully closed nearly $100 million in a Series C financing round. The announcement, made on March 4, 2025, reveals the company’s ambition to enhance global clinical trials, drive international business expansion, and support strategic initiatives critical to its mission.

Leading Investors and Oversubscription

The funding round was notably oversubscribed, reflecting a strong belief in Pulnovo’s vision and technological capabilities. It was co-led by Qiming Venture Partners and existing investor Lilly Asia Ventures, with participation from OrbiMed and Gaorong Capital. This influx of cash represents one of the largest capital raises for innovative medical devices in the Asia-Pacific region in recent years, underlining the confidence of leading institutions in Pulnovo's global strategy.

The Development Path of Pulnovo Medical

Founded in 2013, Pulnovo Medical has steadily established itself as a groundbreaking entity recognized in international guidelines for its market innovation. With its expansive clinical expertise, the company has been at the forefront of advancing both scientific knowledge and global product marketing. Pulnovo is particularly focused on developing superior therapeutic solutions for various stages of heart failure, aiming to improve patient outcomes.

Key Products and Technologies

The hallmark of Pulnovo's offerings is the PADN (Pulmonary Artery Denervation) technology, a minimally invasive and effective treatment for pulmonary hypertension. This revolutionary procedure is approved and market-ready, targeting the pulmonary vascular endothelial sympathetic nerve via radiofrequency ablation. The technique has proven to significantly lower pulmonary artery pressure and delay disease progression, addressing a critical need in combating PH, a condition associated with heart failure and high mortality.

In 2021, PADN garnered FDA breakthrough device status for group I, II, and IV PH conditions, marking a significant milestone. By 2022, it was incorporated into the guidelines of the European Society of Cardiology and the European Respiratory Society. Most recently, 2023 saw Pulnovo receive humanitarian device exemption approvals for group I PH products, with a heart failure catheter and generator set to gain market clearance in China by year-end.

Commitment to Global Health Solutions

Cynthia Chen, Pulnovo Medical's Chair and CEO, indicated that the proceeds from this funding round would be allocated to two crucial FDA studies planned for this year focused on group I and II PH. The leadership team has guided the company’s extraordinary transformation from a laboratory setting to a robust global entity with offices in the United States, Singapore, Hong Kong SAR, and several cities in mainland China, including Beijing and Shanghai.

Insights from Industry Leaders

William Hu, Managing Partner at Qiming Venture Partners, commended Pulnovo’s breakthroughs, highlighting the global availability of PADN technology in Mainland China, Hong Kong, and Macau. He noted that 2024 will see the initiation of multicentric global studies across Portugal, Serbia, Georgia, and Southeast Asia. With the recognition as a breakthrough device from the FDA, Hu stated these worldwide trials validate the leading role and clinical value of the technology. As a dedicated healthcare investor, Qiming is committed to supporting innovative firms with global aspirations, firmly believing in Pulnovo's potential to bring new hope to patients worldwide.

Conclusion

The successful closure of this financing round indicates not only investor confidence but also signifies moving towards a future where Pulnovo Medical can bring innovative treatments to those suffering from pulmonary hypertension and heart failure, enhancing their quality of life and potentially saving lives. With its pioneering PADN technology leading the way, Pulnovo is poised to make significant strides in the realm of cardiovascular health solutions.